Not sure I understand the point. Embeda is not an Elite drug, it is a Pfizer product. Well on the way to reintroduction, but that has nothing to do with the 8 year development time frame for 216. No studies in the last five years. I note in the paper cited that Buddy Berk was an author- maybe he should be brought back to get this moving.
Market Data 
Markets 
AI
